Cambridge City Publishers
  • info.clinical@cardiologycasereportsjournal.org
  • CB1 OBG, Cambridge City, UK
  • Submit Manuscript

Article Details

Case Report
Volume 2, Issue 2 (November Issue)

Pulmonary Vasodilators in LVAD Patients

Roncarati V* and Baiocchi M

Cardiothoracic Anaesthesia and Intensive Care Unit Sant’Orsola University Hospital, Italy

*Corresponding author: Roncarati V, Cardiothoracic Anaesthesia and Intensive Care Unit Sant’Orsola University Hospital, Bologna, Italy.

Received: October 24, 2022; Accepted: November 04, 2022; Published: November 25, 2022

Citation: Roncarati V, Baiocchi M. Pulmonary Vasodilators in LVAD Patients. Case Rep Clin Cardiol J. 2022; 2(2): 117.

Pulmonary Vasodilators in LVAD Patients
Abstract

Left ventricular assist device is a life-saving option in patients with end-stage left heart failure. It leads to a decrease of pulmonary arterial pressure, wedge pressure and pulmonary vascular resistences. However, a post capillary pulmonary hypertension persists in a significant proportion of patients despite adequate LV unloading. A possible explanation is the pulmonary venous congestion and subsequent decrease in the level of nitric oxide. This observation has led to an increased interest for pulmonary vasodilators, especially phosphodiesterase 5 inhibitors (PD-5 I). They enhance the nitric oxide (NO) signaling through the increase of cyclic guanosine monophosphate availability. Sildenafil allows to tritate down the iNO and succesfully extubated the patient; it has been shown to significantly reduce mPAP and PVR 2-4 weeks after LVAD implantation and to wean from inotropic support within the first 72 hours. However, whereas literature seems to support its use in the immediate postoperative period, there are not enough evidences about their long-term use.

Keywords: Pulmonary vasodilators; Patients; Dysfunction